Cardiff Oncology CRDF Stock
Cardiff Oncology Price Chart
Cardiff Oncology CRDF Financial and Trading Overview
| Cardiff Oncology stock price | 1.4 USD |
| Previous Close | 1.9 USD |
| Open | 1.78 USD |
| Bid | 1.26 USD x 200 |
| Ask | 1.8 USD x 200 |
| Day's Range | 1.4 - 1.79 USD |
| 52 Week Range | 1.4 - 4.56 USD |
| Volume | 5.87M USD |
| Avg. Volume | 781.88K USD |
| Market Cap | 101.19M USD |
| Beta (5Y Monthly) | 1.358 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.67 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.69 USD |
CRDF Valuation Measures
| Enterprise Value | 55.78M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8137256 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 192.73799 |
| Price/Book (mrq) | 2.9133859 |
| Enterprise Value/Revenue | 106.243 |
| Enterprise Value/EBITDA | -1.185 |
Trading Information
Cardiff Oncology Stock Price History
| Beta (5Y Monthly) | 1.358 |
| 52-Week Change | -43.28% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 4.56 USD |
| 52 Week Low | 1.4 USD |
| 50-Day Moving Average | 1.69 USD |
| 200-Day Moving Average | 2.08 USD |
CRDF Share Statistics
| Avg. Volume (3 month) | 781.88K USD |
| Avg. Daily Volume (10-Days) | 1.42M USD |
| Shares Outstanding | 68.37M |
| Float | 66.71M |
| Short Ratio | 26.76 |
| % Held by Insiders | 5.91% |
| % Held by Institutions | 32.86% |
| Shares Short | 18.02M |
| Short % of Float | 26.98% |
| Short % of Shares Outstanding | 26.35% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -31341.46% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -44.24% |
| Return on Equity (ttm) | -84.78% |
Income Statement
| Revenue (ttm) | 525K USD |
| Revenue Per Share (ttm) | 0.008 USD |
| Quarterly Revenue Growth (yoy) | -62.39% |
| Gross Profit (ttm) | -31092000 USD |
| EBITDA | -47070000 USD |
| Net Income Avi to Common (ttm) | -44787000 USD |
| Diluted EPS (ttm) | -0.67 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 46.06M USD |
| Total Cash Per Share (mrq) | 0.67 USD |
| Total Debt (mrq) | 646K USD |
| Total Debt/Equity (mrq) | 1.86 USD |
| Current Ratio (mrq) | 3.273 |
| Book Value Per Share (mrq) | 0.508 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -37417000 USD |
| Levered Free Cash Flow (ttm) | -20021500 USD |
Profile of Cardiff Oncology
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 11055 Flintkote Avenue |
| ZIP | 92121 |
| Phone | 858 952 7570 |
| Website | https://www.cardiffoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 30 |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Q&A For Cardiff Oncology Stock
What is a current CRDF stock price?
Cardiff Oncology CRDF stock price today per share is 1.4 USD.
How to purchase Cardiff Oncology stock?
You can buy CRDF shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cardiff Oncology?
The stock symbol or ticker of Cardiff Oncology is CRDF.
Which industry does the Cardiff Oncology company belong to?
The Cardiff Oncology industry is Biotechnology.
How many shares does Cardiff Oncology have in circulation?
The max supply of Cardiff Oncology shares is 68.37M.
What is Cardiff Oncology Price to Earnings Ratio (PE Ratio)?
Cardiff Oncology PE Ratio is now.
What was Cardiff Oncology earnings per share over the trailing 12 months (TTM)?
Cardiff Oncology EPS is -0.67 USD over the trailing 12 months.
Which sector does the Cardiff Oncology company belong to?
The Cardiff Oncology sector is Healthcare.
Cardiff Oncology CRDF included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}